Drug resistance in targeted cancer therapies with RAF inhibitors.

Degirmenci, Ufuk; Yap, Jiajun; Sim, Yuen Rong M; Qin, Shiru; Hu, Jiancheng

Degirmenci, Ufuk; Yap, Jiajun; Sim, Yuen Rong M; Qin, Shiru; Hu, Jiancheng.

Afiliação

Degirmenci U; The Laboratory of Cancer Signaling, National Cancer Centre Singapore, Singapore 169610, Singapore.
Yap J; Authors contributed equally.
Sim YRM; The Laboratory of Cancer Signaling, National Cancer Centre Singapore, Singapore 169610, Singapore.
Qin S; The Cancer and Stem Cell Program, Duke-NUS Medical School, Singapore 169857, Singapore.
Hu J; Authors contributed equally.

Cancer Drug Resist ; 4(3): 665-683, 2021.

Article em En | MEDLINE | ID: mdl-35582307

Palavras-chave

RAF inhibitors; RAF/KSR family kinase; RAS/RAF/MEK/ERK signaling; drug resistance; oncogenic mutation; regulatory spine; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Idioma: En Revista: Cancer Drug Resist Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Singapura

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google